Carlo Ronsini, Stefano Restaino, Manuela Ludovisi, Giuseppe Vizzielli, Mariano Catello Di Donna, Giuseppe Cucinella, Maria Cristina Solazzo, Cono Scaffa, Pasquale De Franciscis, Mario Fordellone, Stefano Cianci, Vito Chiantera
{"title":"炎症指数与CA 125诊断早期卵巢癌:来自意大利多中心前瞻性队列的证据","authors":"Carlo Ronsini, Stefano Restaino, Manuela Ludovisi, Giuseppe Vizzielli, Mariano Catello Di Donna, Giuseppe Cucinella, Maria Cristina Solazzo, Cono Scaffa, Pasquale De Franciscis, Mario Fordellone, Stefano Cianci, Vito Chiantera","doi":"10.3390/jpm15090426","DOIUrl":null,"url":null,"abstract":"<p><p>Ovarian cancer (OC) remains one of the most challenging gynecologic malignancies to diagnose in its early stages, significantly impacting prognosis and treatment options [...].</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470830/pdf/","citationCount":"0","resultStr":"{\"title\":\"Inflammatory Indices vs. CA 125 for the Diagnosis of Early Ovarian Cancer: Evidence from a Multicenter Prospective Italian Cohort.\",\"authors\":\"Carlo Ronsini, Stefano Restaino, Manuela Ludovisi, Giuseppe Vizzielli, Mariano Catello Di Donna, Giuseppe Cucinella, Maria Cristina Solazzo, Cono Scaffa, Pasquale De Franciscis, Mario Fordellone, Stefano Cianci, Vito Chiantera\",\"doi\":\"10.3390/jpm15090426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ovarian cancer (OC) remains one of the most challenging gynecologic malignancies to diagnose in its early stages, significantly impacting prognosis and treatment options [...].</p>\",\"PeriodicalId\":16722,\"journal\":{\"name\":\"Journal of Personalized Medicine\",\"volume\":\"15 9\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470830/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Personalized Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jpm15090426\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15090426","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Inflammatory Indices vs. CA 125 for the Diagnosis of Early Ovarian Cancer: Evidence from a Multicenter Prospective Italian Cohort.
Ovarian cancer (OC) remains one of the most challenging gynecologic malignancies to diagnose in its early stages, significantly impacting prognosis and treatment options [...].
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.